20/04 L1 Group fait le point sur l'introduction en bourse de L1 Gold Fund Limited RE 20/04 L1 Group annonce que l'IPO de L1 Gold Fund a généré 950 millions de dollars australiens MT 14/04 L1 Group ...
14/04 L1 Group fait état de 16 963 millions de dollars australiens d'actifs sous gestion au 31 mars RE 14/04 L1 Group fait état d'une baisse de ses actifs sous gestion au premier trimestre MT 26/03 L1 ...
Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 and TGF-beta, as a treatment for advanced gastric cancer. The green light – ...
Mark Landau, the co-chief investment officer at L1 Capital, uses an example every Australian investor can understand to explain why he and his partner Raphael Lamm see much more exciting opportunities ...